SGN-17/19

N/A

Report date: 2024/12/05 15:15:15

Base Information

Drug NameSGN-17/19

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulantsBeta Lactamase stimulants

TargetsBeta Lactamase

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc Genencor International Inc

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A